NCT01639300View on ClinicalTrials.gov

Safety Study of GNbAC1 in Multiple Sclerosis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

GNbAC1

Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg

BIOLOGICAL

GNbAC1 placebo

Single dose intravenous (IV) GNbAC1 placebo

Trial Locations (2)

1211

Hopitaux Universitaires de Genève - HUG, Geneva

4031

University Hospital Basel, Basel

Sponsors
All Listed Sponsors
lead

GeNeuro Innovation SAS

INDUSTRY